Cagrilintide vs. Semaglutide: Differences, Research, and Access Questions

Cagrilintide and semaglutide are distinct peptides being studied or used in weight management. Semaglutide has published randomized-trial evidence in adults with overweight or obesity, while the cagrilintide and CagriSema sources reviewed here are clinical-trial registrations. CagriSema should not be treated as the same treatment as semaglutide alone.

What are the quick facts about cagrilintide and semaglutide?

The short answer is that cagrilintide and semaglutide are not interchangeable. Semaglutide has published human trial data, including 68-week results from STEP 1, whereas the cagrilintide and CagriSema records in this article are registered research studies. 4 6

Cagrilintide, semaglutide, and CagriSema at a glance

What is established, what is under study, and what patients should not assume

Published semaglutide trials can inform discussions about the active ingredient in the trial setting. They do not establish outcomes for a compounded formulation. For cagrilintide and CagriSema, a registered study is useful evidence that research is occurring, but registration alone does not report a completed study’s results or establish an approved use. 6 8

What are cagrilintide and semaglutide?

Semaglutide is a GLP-1 receptor agonist peptide, while cagrilintide is an investigational peptide designed for the amylin pathway. The clearest evidence difference is that semaglutide has multiple published randomized trials, while the supplied cagrilintide sources are trial records. 1 4 7

Semaglutide: a GLP-1 receptor agonist peptide

Semaglutide is the generic name used in products including Wegovy, Ozempic, and Rybelsus. It is a GLP-1 receptor agonist, meaning it acts on a signaling pathway involved in appetite and blood-sugar regulation. STEP 1 evaluated once-weekly semaglutide in adults with overweight or obesity, and STEP 2 evaluated 2.4 mg once weekly in adults with overweight or obesity and type 2 diabetes. 4 1

Cagrilintide: an investigational amylin analog peptide

Cagrilintide, also called AM833, is an investigational amylin analog peptide. Amylin is a separate appetite-related signaling pathway from GLP-1. A registered phase 1 study is examining cagrilintide’s influence on food intake and appetite in people with overweight or obesity; a separate registered phase 3 study involves people with overweight or obesity and type 2 diabetes. 7 8

What the name CagriSema means

CagriSema is the name used for a cagrilintide-plus-semaglutide combination in registered trials. For example, REDEFINE 3 is listed as an active, not recruiting phase 3 study with planned enrollment of 7,101 participants who have cardiovascular disease. That record describes research, not a published outcome or an individual treatment recommendation. 6

How do GLP-1 and amylin pathways differ?

GLP-1 and amylin are different biological signaling pathways that researchers study in relation to appetite, eating behavior, and metabolic regulation. Two pathways do not automatically mean two times the benefit, and a combination must be judged on its own evidence and safety findings. 4 6

GLP-1 receptor agonists such as semaglutide have published clinical research across weight-management and type 2 diabetes populations. Cagrilintide research focuses on the amylin pathway, including a registered study examining food intake and appetite. Those distinct mechanisms are a reason to avoid assuming the medicines have the same effects, side effects, or eligibility rules. 1 7

If you are sorting through amylin-related headlines, our guides to cagrilintide, the cagrilintide peptide mechanism, and amylin peptide access questions can help separate research terminology from prescription care.

What does research show about semaglutide alone?

Published trials show that semaglutide has been evaluated in randomized studies, including a two-year study in adults with overweight or obesity. These results apply to the active ingredient and the specific study product, dose, population, and monitoring plan—not automatically to every semaglutide formulation. 2

Randomized trials in adults with overweight or obesity

In STEP 1, researchers compared once-weekly semaglutide with placebo in adults with overweight or obesity. In STEP 2, researchers studied semaglutide 2.4 mg once weekly in adults with overweight or obesity and type 2 diabetes. These were randomized phase 3 trials, which are among the stronger study designs for evaluating a treatment in a defined population. 4 1

What longer-term follow-up can and cannot show

STEP 5 reported two-year findings in adults with overweight or obesity. Longer follow-up can add useful information, but it still does not answer every question about a different population, a different formulation, or a person with a different health history. 2

Why safety and monitoring still matter

Semaglutide trials assessed both outcomes and adverse events under structured eligibility and follow-up. The cardiovascular-outcomes SELECT trial also evaluated semaglutide in people with overweight or obesity without diabetes. A clinician should review your medical history, current medicines, pregnancy plans, and symptoms before any prescription decision. 3 4

What is known about cagrilintide and the CagriSema combination?

For cagrilintide and CagriSema, the evidence supplied for this article consists of registered studies, including phase 1 and phase 3 records. These records are valuable for showing the questions researchers are asking, but they are not published efficacy or safety findings. 6 7 8

ClinicalTrials.gov lists a completed phase 3 CagriSema study in East Asia with 331 participants. The completed status means the record identifies the study as completed; it does not, on its own, provide the study’s results or establish that the combination is effective, safe, approved, available, or suitable for an individual. 9

Likewise, the registered cagrilintide phase 3 study in people with overweight or obesity and type 2 diabetes is listed as active, not recruiting, with planned enrollment of 330. A study status should not be read as a product recommendation or a substitute for published peer-reviewed results. 8

How do cagrilintide and semaglutide compare?

The practical comparison is straightforward: semaglutide has published randomized clinical evidence, while cagrilintide and CagriSema remain investigational in this article’s evidence set. The 7,101-participant REDEFINE 3 record does not make CagriSema equivalent to a prescribed semaglutide product. 4 6

Useful questions for a clinician include: What goal am I treating? What evidence applies to my health history? What medicines could interact with treatment? What side effects should prompt a call? And what follow-up plan is available? Those questions matter more than whether a product name is trending online.

What are the safety and eligibility questions to discuss with a clinician?

A clinician should assess safety by the specific product, the person’s health history, and the available evidence—not by social-media comparisons. Individual eligibility can change with current medicines, medical conditions, and pregnancy-related considerations. 1 3

• Ask about expected side effects and what symptoms should lead you to contact the care team.
• Share all prescription medicines, over-the-counter products, supplements, and prior reactions to medications.
• Discuss current or planned pregnancy and breastfeeding before starting or changing treatment.
• Seek urgent medical care for severe or concerning symptoms instead of waiting for an online answer.

Semaglutide trials used defined inclusion criteria and study monitoring, which is one reason trial findings cannot be copied directly into personal care. Cagrilintide and CagriSema combination-specific safety conclusions likewise require published results and clinician interpretation, not a trial-registration page alone. 2 6

How does semaglutide treatment at Chia fit into this discussion?

At Chia, we offer compounded semaglutide injection—not cagrilintide or CagriSema—after a licensed US provider reviews your online health questionnaire. Plans currently start at $249 per month; see our semaglutide treatment page for current details.

If clinically appropriate, our providers guide dosing over time and may offer microdosing plans. Medication is compounded in the United States by state-licensed 503A compounding pharmacies and shipped to eligible patients’ doors. Patients can message their care team through the portal between visits.

Compounded semaglutide is not FDA-approved and is not interchangeable with FDA-approved branded semaglutide products. Published semaglutide trial results describe the products and settings studied; outcomes for compounded formulations are not established by those trials. 1 4

How can patients evaluate online peptide and weight-management options safely?

For prescription care, look for a licensed clinician evaluation and a state-licensed pharmacy rather than a product labeled only for research use. Research-use labeling is not a substitute for diagnosis, prescription review, pharmacy dispensing, or follow-up care.

1. 1Confirm that a licensed clinician reviews your health information before a prescription decision.
2. 2Ask which pharmacy will dispense the medication and how you can contact the care team.
3. 3Bring a complete medication list and relevant health history to the evaluation.
4. 4Be cautious about sellers who present study compounds as though they are established patient treatments.

For a closer look at this issue, read our guide to finding a legitimate peptide source and our overview of research-only products versus prescription access. These resources can help you recognize why clinician oversight and licensed pharmacy dispensing matter.

What are common questions about cagrilintide and semaglutide?

Keep reading

Weight Management

Cheapest Online Weight Loss Programs: How to Compare Cost, Care, and Safety

Weight Management

Wegovy Pen Dosage: Starting Dose, Dose Increases, and Maintenance

Weight Management

Ozempic Doses for Weight Loss: What Patients Should Know